Cadrenal Therapeutics, Inc. Form 8-K Summary
Business Context and Reporting Period
Cadrenal Therapeutics, Inc. (CVKD), a Delaware corporation and emerging growth company, filed this Current Report on Form 8-K on December 23, 2025. The filing addresses Item 8.01 (Other Events) regarding the activation of a portion of its existing "at the market" (ATM) equity offering program.
Key Financial Metrics and Transaction Details
- Offering Capacity: The Company filed a prospectus supplement to offer and sell up to $1,770,028 of its common stock under the ATM Agreement.
- Historical Sales: As of the filing date, the Company has sold an aggregate of $10,005,300 of common stock pursuant to the ATM Agreement since its inception.
- Compensation: The sales agent, H.C. Wainwright & Co., LLC, is entitled to a commission of 3.0% of the gross sales price of shares sold.
- Financial Statements: This filing does not contain revenue, profit, cash flow, margin, debt, or liquidity metrics. The filing text does not provide a clear value for these operational financial indicators.
Material Changes
The primary material change reported is the filing of a new prospectus supplement to enable the sale of an additional $1,770,028 in equity under the existing ATM Agreement dated March 11, 2024. No other material changes to the Company's financial condition or operations are disclosed in this specific report.
Outlook, Risks, and Management Commentary
- Management Discretion: The Company retains the right to set sale parameters, including share count, timing, daily limits, and minimum price thresholds. The Company may suspend or terminate the offering at any time.
- Termination Risks: The ATM Agreement may be terminated by the sales agent upon written notice, including in the event of a material adverse change in the Company.
- Legal Opinion: Blank Rome LLP has issued a legal opinion regarding the validity of the shares to be offered.
- Outlook: The filing does not provide specific forward-looking guidance on product development, clinical trials, or future revenue projections.
Investor Verification Checklist
- Verify the current market price of CVKD common stock to assess potential dilution from the $1,770,028 offering.
- Review the full text of the ATM Agreement (Exhibit 1.1) for specific termination clauses and minimum price restrictions.
- Check recent 10-Q or 10-K filings for the Company's current cash position and burn rate, as this 8-K does not disclose liquidity metrics.
- Confirm the total number of shares outstanding to calculate the percentage dilution of the $10,005,300 already sold plus the new $1,770,028 capacity.